Table 3.

Association between 26 prostate cancer risk SNPs and prostate cancer progression

LocusSNPProstate cancer progression patients, n (%)Non–prostate cancer progression patients, n (%)HR (95% CI)*P
Chr 2: EHBP1rs721048GG161 (70.9)416 (75.8)1.00
GA59 (26.0)124 (22.6)1.12 (0.81-1.54)0.49
AA7 (3.1)9 (1.6)0.96 (0.42-2.21)0.92
Trend1.06 (0.82-1.39)0.65
Chr 2: THADArs1465618GG139 (61.5)342 (62.2)1.00
GA76 (33.6)183 (33.3)1.00 (0.75-1.34)0.99
AA11 (4.9)25 (4.6)1.18 (0.61-2.29)0.62
Trend1.03 (0.81-1.31)0.79
Chr 2: ITGA6rs12621278AA207 (91.2)524 (95.3)1.00
AG20 (8.8)26 (4.7)2.43 (1.51-3.92)0.00026
Chr 3: Intergenicrs2660753CC120 (52.9)319 (57.8)1.00
CT80 (35.2)176 (31.9)1.13 (0.82-1.54)0.45
TT27 (11.9)57 (10.3)1.27 (0.78-2.07)0.34
Trend1.13 (0.90-1.41)0.30
Chr 3: FYC01rs7652331CC103 (45.4)279 (50.5)1.00
CT100 (44.1)214 (38.8)1.39 (1.02-1.89)0.036
TT24 (10.6)59 (10.7)1.09 (0.67-1.77)0.72
Trend1.13 (0.92-1.40)0.26
Chr 3: FYC01rs1545985AA87 (38.3)241 (43.9)1.00
AG115 (50.7)244 (44.4)1.38 (1.03-1.86)0.034
GG25 (11.0)64 (11.7)1.12 (0.70-1.80)0.64
Trend1.14 (0.93-1.40)0.21
Chr 4: LOC152485rs13149290CC135 (59.5)326 (58.7)1.00
CT73 (32.2)192 (34.6)0.88 (0.66-1.18)0.39
TT19 (8.4)37 (6.7)1.06 (0.65-1.73)0.83
Trend0.96 (0.78-1.19)0.73
Chr 4: KIAA1211rs629242CC126 (57.5)333 (61.3)1.00
CT73 (33.3)180 (33.2)1.17 (0.87-1.57)0.30
TT20 (9.1)30 (5.5)1.63 (1.01-2.64)0.047
Trend1.23 (1.00-1.52)0.050
Chr 4: Intergenicrs7679673CC70 (30.8)172 (31.2)1.00
AC113 (49.8)260 (47.2)1.00 (0.74-1.36)0.99
AA44 (19.4)119 (21.6)0.88 (0.59-1.30)0.51
Trend0.94 (0.78-1.14)0.55
Chr 4: PDL1M5rs17021918CC109 (48.0)272 (48.9)1.00
CT96 (42.3)233 (41.9)0.91 (0.69-1.21)0.52
TT22 (9.7)51 (9.2)1.00 (0.63-1.61)0.99
Trend0.97 (0.78-1.19)0.75
Chr 5: FCHSD1rs251177TT119 (52.4)283 (50.8)1.00
TC98 (43.2)223 (40.0)1.04 (0.79-1.37)0.78
CC10 (4.4)51 (9.2)0.63 (0.32-1.21)0.16
Trend0.92 (0.74-1.15)0.75
Chr 6: SLCC22A3rs9364554CC137 (60.4)355 (64.6)1.00
CT73 (32.2)170 (30.9)1.25 (0.91-1.72)0.17
TT17 (7.5)25 (4.6)1.65 (0.97-2.82)0.07
Trend1.27 (1.01-1.61)0.041
Chr 7: LMTK2rs6465657CC80 (35.2)198 (35.7)1.00
CT102 (44.9)238 (43.0)1.18 (0.84-1.65)0.33
TT45 (19.8)118 (21.3)1.29 (0.86-1.95)0.22
Trend1.14 (0.93-1.40)0.21
Chr 7: JAZF1rs10486567GG340 (61.9)137 (60.4)1.00
GA179 (32.6)80 (35.2)0.89 (0.67-1.19)0.43
AA30 (5.5)10 (4.4)0.70 (0.37-1.33)0.28
Trend0.87 (0.69-1.09)0.22
Chr 7: Intergenicrs12155172GG147 (64.8)345 (61.8)1.00
AG66 (29.1)200 (35.8)0.86 (0.64-1.17)0.35
AA14 (6.2)13 (2.3)1.83 (1.05-3.19)0.034
Trend1.07 (0.84-1.35)0.60
Chr 8: Intergenicrs1512268AA57 (25.1)142 (25.6)1.00
GA126 (55.5)256 (46.1)1.46 (1.02-2.08)0.037
GG44 (19.4)157 (28.3)1.22 (0.81-1.85)0.34
Trend1.09 (0.90-1.32)0.39
Chr 9: DAB2IPrs1571801CC147 (64.8)341 (61.7)1.00
CA70 (30.8)184 (33.3)0.91 (0.68-1.22)0.52
AA10 (4.4)28 (5.1)0.86 (0.45-1.63)0.63
Trend0.92 (0.72-1.16)0.46
Chr 10: MSMBrs10993994CC54 (23.9)133 (24.1)1.00
CT115 (50.9)268 (48.5)1.07 (0.77-1.49)0.68
TT57 (25.2)152 (27.5)1.04 (0.71-1.52)0.85
Trend1.02 (0.84-1.23)0.85
Chr 10: CTBP2rs4962416TT118 (52.9)306 (55.1)1.00
TC85 (38.0)199 (35.9)1.05 (0.79-1.40)0.74
CC21 (9.4)50 (9.0)0.99 (0.61-1.60)0.96
Trend1.01 (0.83-1.24)0.89
Chr 11: Intergenicrs10896449AA26 (11.5)104 (18.9)1.00
AG103 (45.4)251 (45.6)1.23 (0.79-1.91)0.36
GG98 (43.2)196 (35.6)1.60 (1.03-2.48)0.037
Trendtrend1.28 (1.04-1.56)0.018
0.0112
Chr 11: Intergenicrs7127900GG125 (55.1)296 (53.8)1.00
AG83 (36.6)228 (41.5)0.86 (0.65-1.15)0.32
AA19 (8.4)26 (4.7)1.42 (0.86-2.36)0.18
Trend1.03 (0.82-1.29)0.83
Chr 13: FAM124Ars10492519AA106 (46.7)265 (46.5)1.00
AG89 (39.2)212 (38.8)0.97 (0.70-1.34)0.86
GG32 (14.1)69 (12.6)1.16 (0.75-1.79)0.51
Trend1.06 (0.85-1.31)0.63
Chr 17: Intergenicrs1859962TT67 (29.5)168 (30.4)1.00
TG99 (43.6)274 (49.6)0.96 (0.69-1.33)0.80
GG61 (26.9)111 (20.1)1.24 (0.86-1.80)0.25
Trend1.12 (0.92-1.35)0.26
Chr 17: HNF1B, TCFrs4430796GG59 (26.0)156 (28.2)1.00
GA95 (41.9)247 (44.6)1.01 (0.72-1.41)0.98
AA73 (32.2)151 (27.3)1.29 (0.90-1.87)0.17
Trend1.14 (0.95-1.38)0.17
Chr 19: KLK2/KLK3rs2735839GG150 (65.8)369 (66.4)1.00
GA67 (29.4)158 (28.4)0.92 (0.68-1.25)0.58
AA11 (4.8)29 (5.2)1.17 (0.62-2.24)0.63
Trend0.99 (0.77-1.27)0.92
Chr X: NUDT10,NUDT11rs5945572GG126 (56.0)380 (68.8)1.00
AA99 (44.0)172 (31.2)1.45 (1.10-1.91)0.008

NOTE: Boldface indicates significant associations (P < 0.05).

  • ↵*Adjusted for age, genetic ancestry, institution, Gleason grade, stage, treatment, and PSA at diagnosis.